KEYNOTE-045: 5-Yr Follow-up of Pembrolizumab in Recurrent Advanced Urothelial Cancer

June 4-8, 2021; Online at https://conferences.asco.org/am
With a median follow-up of 5 years, pembrolizumab continued to show improved overall survival compared with investigator’s choice of chemotherapy in patients with recurrent advanced urothelial cancer on the KEYNOTE-045 trial.
Format: Microsoft PowerPoint (.ppt)
File Size: 467 KB
Released: June 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Exelixis
Merck Sharp & Dohme Corp.

Related Content

Clinical Care Options (CCO): Dr Heather Cheng answers audience questions from a live symposium on current and expanding role of PARP inhibitors in prostate cancer care

Heather H. Cheng, MD, PhD Released: April 26, 2022

Clinical Care Options (CCO): Expert analysis from Drs. Daniel Petrylak and Toni Choueiri on key data in genitourinary cancers from ASCO GU 2022

Toni K. Choueiri, MD Daniel P. Petrylak, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 18, 2022 Expired: April 17, 2023

Clinical Care Options (CCO): Atish Choudhury, MD, PhD, provides insights into new and evolving treatment approaches in CSPC, including data from 2022 ASCO GU Cancers Symposium

Atish Choudhury, MD, PhD Released: March 30, 2022

On-demand Clinical Care Options (CCO) webcast: experts discuss treatment of castration-sensitive prostate cancer, including data from 2022 ASCO GU Cancers Symposium

Atish Choudhury, MD, PhD Michael S. Cookson, MD, MMHC, FACS David F. Jarrard, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: March 14, 2022 Expired: March 13, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings